CJC-1295 DAC vs Tesamorelin

CJC-1295 DAC is based on GHRH(1-29) and includes an albumin affinity complex. Tesamorelin is based on the 44-amino-acid hormone and carries an N-terminal trans-3-hexenoyl modification. Their modifications and underlying lengths differ.

Both entries describe the GHRH receptor and cyclic AMP signaling. That shared pathway does not establish identical degradation, exposure or experimental response. The declared formula and molecular weight for tesamorelin cannot be used to fill missing CJC-1295 DAC fields.

CJC-1295 DAC: CJC-1295 DAC is an analog of the 1-29 fragment of growth hormone-releasing hormone, with an attached maleimide-type albumin affinity complex. In research literature, it binds to the GHRH receptor and acts as an agonist of that pathway. It has been studied in models of prolonged exposure of the somatotropic axis in preclinical research.

Tesamorelin: Tesamorelin is a stabilized analog of the 44-amino-acid human growth hormone-releasing hormone, modified with a trans-3-hexenoyl group at the N-terminus. In research models, it binds to the GHRH receptor in the anterior pituitary and acts on that signaling pathway. It has been studied in models of the somatotropic axis and adipose tissue distribution in preclinical research.

CJC-1295 DAC: The affinity group forms a covalent bond with serum albumin in in vitro studies, modifying the peptide's exposure profile. The molecular target remains the GHRH receptor, which is coupled to Gs protein.

Tesamorelin: The GHRH receptor is a Gs protein-coupled receptor whose activation increases intracellular cyclic AMP in cellular models. The N-terminal modification reduces enzymatic degradation in in vitro studies.

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.